glp 1 covered by blue cross Why Blue Shield is rolling back coverage of GLP-1 weight loss drugs in Massachusetts Blue Cross Blue Shield of

Description

Prebiotic supports digestive health and regularity extends GLP-1 lifespan for prolonged effects on glucose regulation and hunger suppression.*

The FDA has granted accelerated approval of Wegovy (semaglutide) for adults with moderate to advanced metabolic dysfunction-associated steatohepatitis (MASH)

Medications like semaglutide, tirzepatide, liraglutide, and others are defined as GLP-1 meds, and they've revolutionized weight reduction

--- Here are some potential actions covered in the article for payers and employers to take as a result of this shift: Update formulary tiers and step therapy policies (consider the impact on comorbidities) Support members transitioning off GLP-1s after reaching their goals Create differentiated access pathways based on patient risk profiles Monitor realworld outcomes beyond A1C (cardiovascular, renal, adherence) Model the downstream impact on generics and legacy therapies --- Commercial plans are accelerating GLP-1 uptake and favoring the simplicity of a single therapy